Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

13.0K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.0K
Relative Risk01:12

Relative Risk

956
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
956
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

224
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
224
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

54
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
54
Prevalence and Incidence01:08

Prevalence and Incidence

1.1K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.1K
Odds Ratio01:09

Odds Ratio

773
The odds ratio (OR) is a statistical measure used extensively in epidemiology and research to quantify the strength of association between exposure and outcome across different groups. Unlike relative risk, which compares the probabilities of an event occurring, the odds ratio compares the odds of an event occurring in the exposed group to the odds of it occurring in the unexposed group. The odds, in this context, are calculated as the probability of the event happening divided by the...
773

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Humans and rhesus macaques share maturation pathways of HIV-1 envelope-reactive V3-glycan bnAb lineages.

Science translational medicine·2026
Same author

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Acute and longitudinal magnetic resonance imaging abnormalities in antibody-mediated encephalitis.

Brain communications·2026
Same author

Circulatory immune cell counts and clinical outcomes in multiple sclerosis relapse versus remission.

Journal of the neurological sciences·2026

Related Experiment Video

Updated: Nov 9, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study.

Nabil Seery1, Sifat Sharmin2,3, Vivien Li1,4

  • 1Department of Neurology, Melbourne MS Centre, Royal Melbourne Hospital, Parkville, VIC, 3050, Australia.

CNS Drugs
|April 13, 2021
PubMed
Summary

Infections are common in multiple sclerosis (MS) patients on ocrelizumab, but higher immunoglobulin levels (IgA, IgG) and older age may reduce infection risk. Monitoring these factors is crucial for managing ocrelizumab therapy in MS patients.

More Related Videos

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Related Experiment Videos

Last Updated: Nov 9, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.1K
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.3K

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Ocrelizumab (OCR) is a B-cell depleting therapy used for multiple sclerosis (MS).
  • While OCR's safety is established in clinical trials, real-world data on infection risk factors in MS patients are limited.
  • Understanding these factors is crucial for optimizing patient management and safety.

Purpose of the Study:

  • To investigate risk factors for self-reported infections and antimicrobial use in MS patients treated with ocrelizumab.
  • To identify clinical and laboratory predictors of infection and antimicrobial consumption in this population.

Main Methods:

  • Retrospective observational cohort study at a single tertiary hospital.
  • Data collected on patient demographics, clinical history, laboratory values, and self-reported infections and antimicrobial use.
  • Univariate and multivariable logistic regression models used to assess associations.

Main Results:

  • 185 MS patients on ocrelizumab were analyzed; 46.1% reported infections, and 25.3% used antimicrobials.
  • Higher serum IgA and IgG levels, along with older age, were associated with reduced odds of infection.
  • Older age and higher IgA correlated with lower antimicrobial use, while longer MS duration and higher EDSS scores increased antimicrobial use.

Conclusions:

  • Infection risk in MS patients receiving ocrelizumab is variable and influenced by factors like age and immunoglobulin levels.
  • Higher serum IgA and IgG are protective against infections in this cohort.
  • Monitoring immunoglobulin levels pre-treatment and during therapy is recommended to stratify and manage infection risk.